Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 17/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7685037 | 0.99 | EGLN1 (0.70) | EGLN1ALDH1A1PSDKDR | |
| SCHEMBL8309229 | 0.90 | EGLN1 (0.73) | EGLN1ALDH1A1KDR | |
| Hydrochloric Acid SCHEMBL7691042 | 0.89 | EGLN1 (0.71) | EGLN1ALDH1A1 | |
| SCHEMBL7962193 | 0.85 | EGLN1 (0.72) | EGLN1ALDH1A1KDR | |
| SCHEMBL7965479 | 0.85 | EGLN1 (0.72) | EGLN1ALDH1A1PSDKDR | |
| SCHEMBL8311076 | 0.84 | EGLN1 (0.80) | EGLN1ALDH1A1KDR | |
| Hydrochloric Acid SCHEMBL7689878 | 0.84 | EGLN1 (0.67) | EGLN1ALDH1A1 | |
| SCHEMBL2201326 | 0.84 | EGLN1 (1.00) | EGLN1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7690493 | 0.84 | EGLN1 (0.71) | EGLN1ALDH1A1KDR | |
| Hydrochloric Acid SCHEMBL7690327 | 0.84 | EGLN1 (0.70) | EGLN1ALDH1A1PSDKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210205292-A1 | INHIBITORS OF CREB-CBP INTERACTION FOR TREATMENT OF LEUKEMIA | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2021-07-08 | — | — | US | disclosed |
| WO-2017156489-A1 | INHIBITORS OF CREB-CBP INTERACTION FOR TREATMENT OF LEUKEMIA | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2017-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210205292-A1 | INHIBITORS OF CREB-CBP INTERACTION FOR TREATMENT OF LEUKEMIA | CREBBP, CREB1, EP300 | EGLN1 237/4885ALDH1A1 2975/4885PSD 1426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.